Cargando…
Will psilocybin lose its magic in the clinical setting?
Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what psilocybin-assisted psychotherapy might look like in...
Autores principales: | Hayes, Caroline, Wahba, Mourad, Watson, Stuart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036342/ https://www.ncbi.nlm.nih.gov/pubmed/35480296 http://dx.doi.org/10.1177/20451253221090822 |
Ejemplares similares
-
Classic psychedelics, health behavior, and physical
health
por: Simonsson, Otto, et al.
Publicado: (2022) -
Psychedelic treatment of functional neurological disorder: a systematic review
por: Butler, Matthew, et al.
Publicado: (2020) -
The therapeutic potential of microdosing psychedelics in depression
por: Kuypers, Kim P.C.
Publicado: (2020) -
Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019) -
Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study
por: Glue, Paul, et al.
Publicado: (2020)